

### SECTION 1: IDENTIFICATION

#### 1.1. Product Identifier

**Product Form:** Mixture

**Product Name:** Butatron Tablet (phenylbutazone tablets)

#### 1.2. Intended Use of the Product

**Use of the substance/mixture:** Veterinary Anti-inflammatory

#### 1.3. Name, Address, and Telephone of the Responsible Party

##### Company

Bimeda Inc.

One Tower Lane

Oakbrook Terrace Tower

Oakbrook Terrace, IL 60181

T 630-928-0361

F 630-928 0362

[www.bimedaus.com](http://www.bimedaus.com)

#### 1.4. Emergency Telephone Number

**Emergency Number** : 519-654-8055, 800-424-9300 CHEMTREC (in US); +1 703-527-3887 CHEMTREC (International and Maritime)

### SECTION 2: HAZARDS IDENTIFICATION

#### 2.1. Classification of the Substance or Mixture

**Patients/Consumers:** Please refer to the product information insert or product label for appropriate consumer-specific information about this product when used according to the physician's directions. Pharmaceutical Agent – Handling of this product in its final form presents minimal occupational exposure risk.

This product is a drug, as defined by the US Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.).

##### GHS-US classification

Comb. Dust

Acute Tox. 4 (Oral) H302

Acute Tox. 4 H332

(Inhalation:dust,mist)

Skin Irrit. 2 H315

Eye Irrit. 2A H319

Resp. Sens. 1 H334

Skin Sens. 1 H317

Carc. 2 H351

Full text of H-phrases: see section 16

#### 2.2. Label Elements

##### GHS-US Labeling

##### Hazard Pictograms (GHS-US)



##### Signal Word (GHS-US)

: Danger

##### Hazard Statements (GHS-US)

: May form combustible dust concentrations in air.  
 H302+H332 - Harmful if swallowed or if inhaled.  
 H315 - Causes skin irritation.  
 H317 - May cause an allergic skin reaction.  
 H319 - Causes serious eye irritation.  
 H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
 H351 - Suspected of causing cancer.

##### Precautionary Statements (GHS-US)

: P201 - Obtain special instructions before use.  
 P202 - Do not handle until all safety precautions have been read and understood.  
 P261 - Avoid breathing vapors, mist, or spray.  
 P264 - Wash hands, forearms, and other exposed areas thoroughly after handling.  
 P270 - Do not eat, drink or smoke when using this product.

# Butatron Tablet (phenylbutazone tablets)

## Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

P271 - Use only outdoors or in a well-ventilated area.  
P272 - Contaminated work clothing must not be allowed out of the workplace.  
P280 - Wear protective gloves, protective clothing, and eye protection.  
P284 - [In case of inadequate ventilation] wear respiratory protection .  
P301+P312 - If swallowed: Call a poison center or doctor if you feel unwell.  
P302+P352 - If on skin: Wash with plenty of water.  
P304+P340 - If inhaled: Remove person to fresh air and keep at rest in a position comfortable for breathing.  
P305+P351+P338 - If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
P308+P313 - If exposed or concerned: Get medical advice/attention.  
P312 - Call a poison center or doctor if you feel unwell.  
P321 - Specific treatment (see section 4 on this SDS).  
P330 - Rinse mouth.  
P333+P313 - If skin irritation or rash occurs: Get medical advice/attention.  
P337+P313 - If eye irritation persists: Get medical advice/attention.  
P342+P311 - If experiencing respiratory symptoms: Call a poison center or doctor.  
P362+P364 - Take off contaminated clothing and wash it before reuse.  
P405 - Store locked up.  
P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations.

### 2.3. Other Hazards

Exposure may aggravate pre-existing eye, skin, or respiratory conditions.

### 2.4. Unknown Acute Toxicity (GHS-US)

No data available

## SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1. Substance

Not applicable

### 3.2. Mixture

Name	Product Identifier	%	GHS-US classification
Proprietary Component A*	(CAS No) Trade Secret	38.9	Comb. Dust
Phenylbutazone	(CAS No) 50-33-9	33	Acute Tox. 4 (Oral), H302 Acute Tox. 4 (Dermal), H312 Acute Tox. 4 (Inhalation), H332 Skin Irrit. 2, H315 Eye Irrit. 2A, H319 Resp. Sens. 1, H334 Skin Sens. 1, H317 Carc. 2, H351
Proprietary Component B*	(CAS No) Trade Secret	17.2	Comb. Dust
Proprietary Component C*	(CAS No) Trade Secret	9.3	Comb. Dust
Proprietary Component D*	(CAS No) Trade Secret	1.1	Comb. Dust
Proprietary Component E*	(CAS No) Trade Secret	0.5	Comb. Dust

Full text of H-phrases: see section 16

The specific chemical identity and/or exact percentage of composition have been withheld as a trade secret in accordance with Paragraph 1910.1200 of Title 29 of the Code of Federal Regulations.

## SECTION 4: FIRST AID MEASURES

### 4.1. Description of First Aid Measures

**First-aid Measures General:** Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice (show the label where possible).

**First-aid Measures After Inhalation:** Remove to fresh air and keep at rest in a position comfortable for breathing. Get medical advice/attention. Using proper respiratory protection, move the exposed person to fresh air at once. Encourage exposed person to cough, spit out, and blow nose to remove dust. Immediately call a poison center, physician, or emergency medical service.

# Butatron Tablet (phenylbutazone tablets)

## Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

**First-aid Measures After Skin Contact:** Remove contaminated clothing. Drench affected area with water for at least 15 minutes. Obtain medical attention if irritation develops or persists.

**First-aid Measures After Eye Contact:** Rinse cautiously with water for at least 15 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Obtain medical attention.

**First-aid Measures After Ingestion:** Rinse mouth. Do NOT induce vomiting. Obtain medical attention.

### 4.2. Most important symptoms and effects, both acute and delayed

**Symptoms/Injuries:** Causes serious eye irritation. Causes skin irritation. Harmful if swallowed. Harmful if inhaled. May cause allergy or asthma symptoms or breathing difficulties if inhaled. Skin sensitization. Suspected of causing cancer.

**Symptoms/Injuries After Inhalation:** Inhalation is likely to cause adverse health effects including but not limited to: irritation, difficulty breathing, and unconsciousness. Exposure may produce cough mucous secretions, shortness of breath, chest tightness or other symptoms indicative of an allergic/sensitization reaction. Dust may be harmful or cause irritation.

**Symptoms/Injuries After Skin Contact:** Redness, pain, swelling, itching, burning, dryness, and dermatitis. May cause an allergic skin reaction.

**Symptoms/Injuries After Eye Contact:** Contact causes severe irritation with redness and swelling of the conjunctiva.

**Symptoms/Injuries After Ingestion:** This material is harmful orally and can cause adverse health effects or death in significant amounts.

**Chronic Symptoms:** Suspected of causing cancer.

### 4.3. Indication of Any Immediate Medical Attention and Special Treatment Needed

If exposed or concerned, get medical advice and attention. If medical advice is needed, have product container or label at hand.

## SECTION 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing Media

**Suitable Extinguishing Media:** Use extinguishing media appropriate for surrounding fire.

**Unsuitable Extinguishing Media:** Do not use a heavy water stream. Use of heavy stream of water may spread fire.

### 5.2. Special Hazards Arising From the Substance or Mixture

**Fire Hazard:** Combustible Dust.

**Explosion Hazard:** Dust explosion hazard in air.

**Reactivity:** Hazardous reactions will not occur under normal conditions.

### 5.3. Advice for Firefighters

**Precautionary Measures Fire:** Exercise caution when fighting any chemical fire.

**Firefighting Instructions:** Use water spray or fog for cooling exposed containers.

**Protection During Firefighting:** Do not enter fire area without proper protective equipment, including respiratory protection.

**Other Information:** Risk of dust explosion.

## SECTION 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal Precautions, Protective Equipment and Emergency Procedures

**General Measures:** Do not breathe dust. Do not get in eyes, on skin, or on clothing. Avoid generating dust. Remove ignition sources. Keep away from heat, hot surfaces, sparks, open flames, and other ignition sources. No smoking.

#### 6.1.1. For Non-emergency Personnel

**Protective Equipment:** Use appropriate personal protection equipment (PPE).

**Emergency Procedures:** Evacuate unnecessary personnel.

#### 6.1.2. For Emergency Responders

**Protective Equipment:** Equip cleanup crew with proper protection.

**Emergency Procedures:** Ventilate area. Upon arrival at the scene, a first responder is expected to recognize the presence of dangerous goods, protect oneself and the public, secure the area, and call for the assistance of trained personnel as soon as conditions permit.

### 6.2. Environmental Precautions

Prevent entry to sewers and public waters.

### 6.3. Methods and Material for Containment and Cleaning Up

**For Containment:** Contain solid spills with appropriate barriers and prevent migration and entry into sewers or streams. As an immediate precautionary measure, isolate spill or leak area in all directions. Ventilate area. Avoid generation of dust during clean-up of spills.

**Methods for Cleaning Up:** Clean up spills immediately and dispose of waste safely. Contact competent authorities after a spill. Use explosion proof vacuum during cleanup, with appropriate filter. Do not mix with other materials. Vacuum clean-up is preferred. If sweeping is required use a dust suppressant. Use only non-sparking tools.

### 6.4. Reference to Other Sections

See Heading 8. Exposure controls and personal protection. See Section 13, Disposal Considerations.

# Butatron Tablet (phenylbutazone tablets)

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

## SECTION 7: HANDLING AND STORAGE

### 7.1. Precautions for Safe Handling

**Additional Hazards When Processed:** Accumulation and dispersion of dust with an ignition source can cause a combustible dust explosion. Keep dust levels to a minimum and follow applicable regulations.

**Precautions for Safe Handling:** Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when leaving work. Handle empty containers with care because they may still present a hazard. Do not get in eyes, on skin, or on clothing. Use only outdoors or in a well-ventilated area. Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dust. Avoid creating or spreading dust. Keep away from heat, sparks, open flames, hot surfaces. – No smoking.

**Hygiene Measures:** Handle in accordance with good industrial hygiene and safety procedures.

### 7.2. Conditions for Safe Storage, Including Any Incompatibilities

**Technical Measures:** Comply with applicable regulations. Avoid creating or spreading dust. Use explosion-proof electrical, ventilating, lighting equipment. Proper grounding procedures to avoid static electricity should be followed.

**Storage Conditions:** Keep container closed when not in use. Store in a dry, cool place. Keep/Store away from direct sunlight, extremely high or low temperatures and incompatible materials.

**Incompatible Products:** Strong acids, strong bases, strong oxidizers.

### 7.3. Specific End Use(s)

Veterinary Anti-inflammatory

## SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control Parameters

For substances listed in section 3 that are not listed here, there are no established exposure limits from the manufacturer, supplier, importer, or the appropriate advisory agency including: ACGIH (TLV), AIHA (WEEL), NIOSH (REL), or OSHA (PEL).

Proprietary Component B		
USA ACGIH	ACGIH TWA (mg/m <sup>3</sup> )	10 mg/m <sup>3</sup>
USA NIOSH	NIOSH REL (TWA) (mg/m <sup>3</sup> )	10 mg/m <sup>3</sup> (total dust) 5 mg/m <sup>3</sup> (respirable dust)
USA OSHA	OSHA PEL (TWA) (mg/m <sup>3</sup> )	15 mg/m <sup>3</sup> (total dust) 5 mg/m <sup>3</sup> (respirable fraction)

### 8.2. Exposure Controls

#### Appropriate Engineering Controls

: Emergency eye wash fountains and safety showers should be available in the immediate vicinity of any potential exposure. Ensure adequate ventilation, especially in confined areas. Ensure all national/local regulations are observed. Gas detectors should be used when toxic gases may be released. Proper grounding procedures to avoid static electricity should be followed. Use explosion-proof equipment. Use local exhaust or general dilution ventilation or other suppression methods to maintain dust levels below exposure limits. Power equipment should be equipped with proper dust collection devices. It is recommended that all dust control equipment such as local exhaust ventilation and material transport systems involved in handling of this product contain explosion relief vents or an explosion suppression system or an oxygen-deficient environment.

#### Personal Protective Equipment

: Gloves. Protective clothing. Protective goggles. Insufficient ventilation: wear respiratory protection.



#### Materials for Protective Clothing

: Chemically resistant materials and fabrics.

#### Hand Protection

: Wear protective gloves.

#### Eye Protection

: Chemical safety goggles.

#### Skin and Body Protection

: Wear suitable protective clothing.

#### Respiratory Protection

: If exposure limits are exceeded or irritation is experienced, approved respiratory protection should be worn. In case of inadequate ventilation, oxygen deficient atmosphere, or where exposure levels are not known wear approved respiratory protection.

#### Other Information

: When using, do not eat, drink or smoke.

# Butatron Tablet (phenylbutazone tablets)

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

## SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on Basic Physical and Chemical Properties

Physical State	: Solid
Appearance	: White Tablet
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Evaporation Rate	: No data available
Melting Point	: No data available
Freezing Point	: No data available
Boiling Point	: No data available
Flash Point	: No data available
Auto-ignition Temperature	: No data available
Decomposition Temperature	: No data available
Flammability (solid, gas)	: No data available
Vapor Pressure	: No data available
Relative Vapor Density at 20 °C	: No data available
Relative Density	: No data available
Solubility	: No data available
Partition Coefficient: N-Octanol/Water	: No data available
Viscosity	: No data available

9.2. Other Information No additional information available

## SECTION 10: STABILITY AND REACTIVITY

- 10.1. **Reactivity:** Hazardous reactions will not occur under normal conditions.
- 10.2. **Chemical Stability:** Stable under recommended handling and storage conditions (see section 7).
- 10.3. **Possibility of Hazardous Reactions:** Hazardous polymerization will not occur.
- 10.4. **Conditions to Avoid:** Direct sunlight, extremely high or low temperatures, and incompatible materials. Sparks, heat, open flame and other sources of ignition.
- 10.5. **Incompatible Materials:** Strong acids, strong bases, strong oxidizers.
- 10.6. **Hazardous Decomposition Products:** Not available

## SECTION 11: TOXICOLOGICAL INFORMATION

### 11.1. Information On Toxicological Effects

**Acute Toxicity:** Oral: Harmful if swallowed. Inhalation:dust,mist: Harmful if inhaled.

Butatron Tablet (phenylbutazone tablets)	
ATE (Oral)	742.42 mg/kg body weight
ATE (Dust/Mist)	4.55 mg/l/4h
Phenylbutazone (50-33-9)	
LD50 Oral Rat	245 mg/kg
ATE (Dermal)	1,100.00 mg/kg body weight
ATE (Gases)	4,500.00 ppmV/4h
ATE (Vapors)	11.00 mg/l/4h
ATE (Dust/Mist)	1.50 mg/l/4h
Proprietary Component B	
LD50 Oral Rat	> 5000 mg/kg
LD50 Dermal Rabbit	> 2000 mg/kg
LC50 Inhalation Rat	> 5800 mg/m <sup>3</sup> (Exposure time: 4 h)
Proprietary Component E	
LD50 Oral Rat	> 2000 mg/kg
LC50 Inhalation Rat	> 2 mg/l/4h
Proprietary Component D	
LD50 Oral Rat	100000 mg/kg

# Butatron Tablet (phenylbutazone tablets)

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

ATE (Oral)	100,000.00 mg/kg body weight
------------	------------------------------

**Skin Corrosion/Irritation:** Causes skin irritation.

**Serious Eye Damage/Irritation:** Causes serious eye irritation.

**Respiratory or Skin Sensitization:** May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause an allergic skin reaction.

**Germ Cell Mutagenicity:** Not classified

**Carcinogenicity:** Suspected of causing cancer.

<b>Phenylbutazone (50-33-9)</b>	
---------------------------------	--

IARC group	3
------------	---

<b>Proprietary Component D</b>	
--------------------------------	--

IARC group	3
------------	---

**Reproductive Toxicity:** Not classified

**Specific Target Organ Toxicity (Single Exposure):** Not classified

**Specific Target Organ Toxicity (Repeated Exposure):** Not classified

**Aspiration Hazard:** Not classified

**Symptoms/Injuries After Inhalation:** Inhalation is likely to cause adverse health effects including but not limited to: irritation, difficulty breathing, and unconsciousness. Exposure may produce cough mucous secretions, shortness of breath, chest tightness or other symptoms indicative of an allergic/sensitization reaction. Dust may be harmful or cause irritation.

**Symptoms/Injuries After Skin Contact:** Redness, pain, swelling, itching, burning, dryness, and dermatitis. May cause an allergic skin reaction.

**Symptoms/Injuries After Eye Contact:** Contact causes severe irritation with redness and swelling of the conjunctiva.

**Symptoms/Injuries After Ingestion:** This material is harmful orally and can cause adverse health effects or death in significant amounts.

**Chronic Symptoms:** Suspected of causing cancer.

## SECTION 12: ECOLOGICAL INFORMATION

### 12.1. Toxicity

Ecology - General : Not classified.

### 12.2. Persistence and Degradability

<b>Butatron Tablet (phenylbutazone tablets)</b>	
Persistence and Degradability	Not established.

### 12.3. Bioaccumulative Potential

<b>Butatron Tablet (phenylbutazone tablets)</b>	
Bioaccumulative Potential	Not established.

**12.4. Mobility in Soil** No additional information available

### 12.5. Other Adverse Effects

**Other Information** : Avoid release to the environment.

## SECTION 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

**Waste Disposal Recommendations:** Dispose of contents/container in accordance with local, regional, national, and international regulations.

**Additional Information:** Container may remain hazardous when empty. Continue to observe all precautions.

**Ecology – Waste Materials:** Avoid release to the environment.

## SECTION 14: TRANSPORT INFORMATION

**14.1. In Accordance with DOT** Not regulated for transport

**14.2. In Accordance with IMDG** Not regulated for transport

**14.3. In Accordance with IATA** Not regulated for transport

## SECTION 15: REGULATORY INFORMATION

### 15.1 US Federal Regulations

<b>Butatron Tablet (phenylbutazone tablets)</b>	
SARA Section 311/312 Hazard Classes	Immediate (acute) health hazard
<b>Phenylbutazone (50-33-9)</b>	
Listed on the United States TSCA (Toxic Substances Control Act) inventory	

# Butatron Tablet (phenylbutazone tablets)

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

<b>Proprietary Component B</b>
Listed on the United States TSCA (Toxic Substances Control Act) inventory
<b>Proprietary Component C</b>
Listed on the United States TSCA (Toxic Substances Control Act) inventory
<b>Proprietary Component E</b>
Listed on the United States TSCA (Toxic Substances Control Act) inventory
<b>Proprietary Component D</b>
Listed on the United States TSCA (Toxic Substances Control Act) inventory

## 15.2 US State Regulations

<b>Proprietary Component B</b>
U.S. - Massachusetts - Right To Know List
U.S. - New Jersey - Right to Know Hazardous Substance List
U.S. - Pennsylvania - RTK (Right to Know) List

## SECTION 16: OTHER INFORMATION, INCLUDING DATE OF PREPARATION OR LAST REVISION

<b>Revision Date</b>	: 11/30/2015
<b>Other Information</b>	: This document has been prepared in accordance with the SDS requirements of the OSHA Hazard Communication Standard 29 CFR 1910.1200.

### GHS Full Text Phrases:

Acute Tox. 4 (Dermal)	Acute toxicity (dermal) Category 4
Acute Tox. 4 (Inhalation)	Acute toxicity (inhalation) Category 4
Acute Tox. 4 (Inhalation:dust,mist)	Acute toxicity (inhalation:dust,mist) Category 4
Acute Tox. 4 (Oral)	Acute toxicity (oral) Category 4
Carc. 2	Carcinogenicity Category 2
Comb. Dust	Combustible Dust
Eye Irrit. 2A	Serious eye damage/eye irritation Category 2A
Resp. Sens. 1	Respiratory sensitisation Category 1
Skin Irrit. 2	Skin corrosion/irritation Category 2
Skin Sens. 1	Skin sensitization Category 1
H232	May form combustible dust concentrations in air
H302	Harmful if swallowed
H312	Harmful in contact with skin
H315	Causes skin irritation
H317	May cause an allergic skin reaction
H319	Causes serious eye irritation
H332	Harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H351	Suspected of causing cancer

*This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.*

SDS US (GHS HazCom)